Accessibility Menu
Eupraxia Pharmaceuticals logo

Eupraxia Pharmaceuticals(NASDAQ) EPRX

Current Price$5.81
Market Cap$379.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+108%
5 YearN/A
1 Year+5%
1 Month-7%
Eupraxia Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 5.812026-07-24
Eupraxia Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.84%USD 6.592026-07-17
1 month-7.04%USD 6.252026-06-24
3 month-18.85%USD 7.162026-04-24
Year to date-23.05%USD 7.552025-12-31
1 year+4.87%USD 5.542025-07-24
3 year-1.36%USD 5.892023-07-24
Since inception+108.32%USD 2.792021-08-03

Eupraxia Pharmaceuticals Financials at a Glance

Market Cap

$379.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$42.49M

EPS (TTM)

-$1.02

P/E Ratio

-5.71

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$5.81

Volume

892,500.435

Open

$6.37

Previous Close

$5.81

Daily Range

$5.72 - $6.37

52-Week Range

$5.04 - $9.32

Estimated Earnings Date

Aug 11, 2026

EPRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing innovative products to address significant therapeutic needs. Utilizing proprietary Diffusphere technology, the company aims to optimize drug delivery for various medical applications.

Products and Services
  • EP-104IAR: Phase III trial for knee osteoarthritis treatment
  • EP-104GI: Phase II trial for eosinophilic esophagitis
  • EP-104: Preclinical studies for gastrointestinal tract conditions
Growth Outlook
  • Strong pipeline with multiple products in advanced clinical trials
  • Significant market potential in unmet therapeutic areas
  • Recent funding boosts to support ongoing research and development
Financial Highlights
  • Recent quarterly net income of -$12.48 million, reflecting ongoing investment in R&D
  • Cash and short-term investments of $138.88 million, providing a solid financial foundation
  • Current ratio of 19.30, indicating strong liquidity and financial health
Eupraxia Pharmaceuticals Inc. is positioned in the biotechnology sector, focusing on unmet medical needs through innovative drug delivery systems. The company's product pipeline includes promising candidates that are currently undergoing clinical trials, which could lead to significant market opportunities. Recent financial data indicates a robust cash position, allowing for continued investment in research and development. The current ratio suggests a strong ability to meet short-term obligations, enhancing the company's financial stability. Overall, Eupraxia Pharmaceuticals Inc. presents an intriguing opportunity for investors interested in the biotechnology field.
AI Generated • Jul 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

21

CEO

James A. Helliwell, MD

Website

www.eupraxiapharma.com

Headquarters

Victoria, BC V8R 5G4, CA

EPRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-53.61%

Return on Capital

-65.28%

Return on Assets

-30.60%

Earnings Yield

-17.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$379.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

65.33M

Volume

892.50K

Avg. Volume

316.34K

Financials (TTM)

Gross Profit

-$151.18K

Operating Income

-$47.27M

EBITDA

-$45.49M

Operating Cash Flow

-$31.43M

Capital Expenditure

-$728.23K

Free Cash Flow

-$32.16M

Cash & ST Invst.

$138.88M

Total Debt

$2.01M

Eupraxia Pharmaceuticals Performance Analysis

Eupraxia Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Eupraxia Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Eupraxia Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.96-25.5%
20232023-12-31USD -1.1721.9%
20242024-12-31USD -0.75-35.7%
20252025-12-31USD -1.0336.9%
Eupraxia Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-14.3%
Q32025-09-30N/A
Q42025-12-31-41.7%
Q12026-03-3132.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$88.90K

N/A

Gross Margin

0.00%

N/A

Market Cap

$379.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.75M

N/A

Employees

49

N/A

Net Income

-$12.48M

-84.5%

EBITDA

-$15.65M

-132.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$138.88M

+405.8%

Total Debt

$2.01M

+3702.6%

Accounts Receivable

$663.24K

+178.0%

Inventory

$0.00

N/A

Long Term Debt

$1.80M

N/A

Short Term Debt

$203.51K

+285.6%

Return on Assets

-30.60%

N/A

Return on Invested Capital

-34.22%

N/A

Free Cash Flow

-$10.33M

-67.3%

Operating Cash Flow

-$10.01M

-66.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNFTGenfit S.A.
$8.95+4.07%
IVAInventiva S.A.
$4.46-1.11%
RNACCartesian Therapeutics, Inc.
$7.88-0.51%
TARAProtara Therapeutics, Inc.
$4.02-0.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About EPRX

What is the current price of Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals is trading at $5.81 per share.

What is the 52-week range for Eupraxia Pharmaceuticals?

Over the past 52 weeks, Eupraxia Pharmaceuticals has traded between $5.04 and $9.32.

How much debt does Eupraxia Pharmaceuticals have?

As of the most recent reporting period, Eupraxia Pharmaceuticals reported total debt of $2.01M.

How much cash does Eupraxia Pharmaceuticals have on hand?

Eupraxia Pharmaceuticals reported $58.50M in cash and cash equivalents in its most recent financial results.

What is Eupraxia Pharmaceuticals’s dividend yield?

Eupraxia Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services